A new study titled ‘Longitudinal monitoring of circulating tumor cell dynamics for potential prediction of early recurrence and clinical outcomes after curative resection of hepatocellular carcinoma: a pilot study,’ published in the January 29 edition of BMC Cancer, adds to growing evidence that liquid biopsy technologies are poised to transform cancer monitoring, particularly in diseases such as hepatocellular carcinoma (HCC), where recurrence rates remain high even after apparently curative surgery.[1]
The study by Roy et al. demonstrates that tracking circulating tumor cells (CTCs) over time can provide an early and non-invasive window into minimal residual disease and recurrence risk in HCC patients following hepatectomy.[1]
Persistent Challenge of Recurrence in HCC
Hepatocellular carcinoma is among the most common and lethal cancers worldwide, particularly in regions with high prevalence of chronic hepatitis B and C infection. While surgical resection remains one of the few potentially curative options, recurrence rates are notoriously high, often exceeding 50 percent within five years. Current post-surgical surveillance relies heavily on imaging modalities such as CT or MRI and serum biomarkers like alpha-fetoprotein (AFP). However, these tools often detect recurrence only after tumors have reached a clinically significant size, limiting opportunities for early intervention.
Liquid biopsy, which involves analyzing tumor-derived material in blood or other biofluids, has emerged as a promising alternative. Among the various analytes available, circulating tumor cells and ctDNA are considered especially informative, as they reflect active tumor biology in real time.
Design of the Study
In the new study, Roy et al. prospectively analyzed CTC dynamics in 27 HCC patients undergoing curative resection. Blood samples were collected at four time points: preoperatively, immediately postoperatively, and at 6 and 12 months after surgery. CTCs were defined using a multicolor immunophenotyping approach, specifically as CD45-negative, CD146-positive, and ASGPR-positive cells. These markers were selected to distinguish hepatocyte-derived malignant cells from normal blood cells. Detection was performed using flow cytometry and immunofluorescence, enabling both quantitative and qualitative assessment.
Two control groups were also included: 29 patients with non-malignant or non-HCC liver tumors, and 8 healthy donors. Clinical outcomes were assessed over a median follow-up of 3.7 years, with recurrence-free survival (RFS) and overall survival (OS) as primary endpoints.
Key Findings: CTCs as Early Indicators
This prospective study shows that persistent and rising CTCs after curative hepatectomy are strong predictors of early recurrence and poor survival in HCC. Preoperative CTCs were detected in 48.2 percent of HCC patients, with a mean concentration of 0.46 cells per milliliter of blood. However, detection rates rose dramatically after surgery: 95 percent at six months and 100 percent at 12 months. Most strikingly, patients with persistent or rising postoperative CTC levels experienced significantly worse outcomes. Overall, 51.8 percent of patients developed recurrence during follow-up.
Those with elevated CTCs showed significantly reduced RFS (p = 0.02) and OS (p = 0.05). Importantly, CTC levels did not correlate with traditional clinical parameters, including tumor size, tumor volume, AFP, or IL-6 levels. This suggests that CTCs provide independent prognostic information not captured by standard markers.
The authors conclude that persistent CTCs likely represent minimal residual disease, offering a molecular explanation for recurrence that precedes radiographic or clinical detection.
Overall, the findings reinforce CTCs as a dynamic, non-invasive biomarker for MRD and early recurrence in HCC. Integrating longitudinal CTC monitoring into postoperative surveillance could improve risk stratification, enable earlier intervention, and guide adjuvant therapy decisions beyond conventional clinicopathological markers.
From Pilot Study to Broader Liquid Biopsy Framework
“Persistent CTCs are not just indicators of disease; they may be the seeds of future tumors,” Dhruvajyoti Roy, Ph.D., said.
“Targeting these cells therapeutically could open entirely new avenues for preventing recurrence,” he added.
Looking ahead, larger multicenter trials will be needed to validate the findings and establish standardized thresholds for clinical use.
According to Roy, the central philosophy of this collaborative research is that “cancer leaves measurable molecular footprints in the bloodstream long before it becomes clinically visible,” and that combining orthogonal technologies can improve both sensitivity and specificity.
The new HCC pilot study represents one piece of this larger vision. While modest in size, it provides compelling evidence that the future of post-surgical cancer care may lie not in periodic scans, but in continuous molecular surveillance through liquid biopsy.
Integrating CTC dynamics with ctDNA and methylation data could further refine risk stratification models.
Reference:
[1] Roy D, Guckelberger O, Oppermann E, Büdeyri I, Chaikhoun R, Kohl N, Kostantin M, Zokai D, Knaak M, Katou S, Becker F, Andreou A, Morgul H, Struecker B, Zharov VP, Schnitzbauer A, Vogl TJ, Bechstein WO, Pascher A, Zimmermann MS, Juratli MA. Longitudinal monitoring of circulating tumor cell dynamics for potential prediction of early recurrence and clinical outcomes after curative resection of hepatocellular carcinoma: a pilot study. BMC Cancer. 2026 Jan 29. doi.org/10.1186/s12885-026-15638-7. Epub ahead of print. PMID: 41606522.
Featured image © 2023 – 2026 licensed under the Unsplash+ License. used with permission.
DO
 over time can provide an early and non-invasive window into minimal residual disease and recurrence risk in HCC patients following hepatectomy.){kind=link}